Oral and intranasal aspirin desensitisation for non‐steroidal anti‐inflammatory drug (NSAID)‐exacerbated respiratory disease
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Oral and Intranasal Aspirin Desensitisation for Non‐steroidal Anti‐inflammatory Drug (NSAID)‐exacerbated Respiratory Disease." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/435968/all/Bezafibrate_for_primary_biliary_cirrhosis:_Cochrane_systematic_review. Accessed 29 March 2024.
Oral and intranasal aspirin desensitisation for non‐steroidal anti‐inflammatory drug (NSAID)‐exacerbated respiratory disease. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/435968/all/Bezafibrate_for_primary_biliary_cirrhosis:_Cochrane_systematic_review. Accessed March 29, 2024.
Oral and intranasal aspirin desensitisation for non‐steroidal anti‐inflammatory drug (NSAID)‐exacerbated respiratory disease. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/435968/all/Bezafibrate_for_primary_biliary_cirrhosis:_Cochrane_systematic_review
Oral and Intranasal Aspirin Desensitisation for Non‐steroidal Anti‐inflammatory Drug (NSAID)‐exacerbated Respiratory Disease [Internet]. In: Cochrane Abstracts. [cited 2024 March 29]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/435968/all/Bezafibrate_for_primary_biliary_cirrhosis:_Cochrane_systematic_review.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Oral and intranasal aspirin desensitisation for non‐steroidal anti‐inflammatory drug (NSAID)‐exacerbated respiratory disease
ID - 435968
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/435968/all/Bezafibrate_for_primary_biliary_cirrhosis:_Cochrane_systematic_review
DB - Evidence Central
DP - Unbound Medicine
ER -